Kezar Life Sciences Q1 2023 net loss $22.2M; cash $257.7M; trials on track

Kezar Life Sciences, Inc.

2023-Q1 EPS reported -$0.31

Net loss of $22.2M ($0.31 per share) vs $16.0M ($0.26 per share) in Q1 2022.
Cash, cash equivalents and marketable securities $257.7M as of March 31, 2023, down from $276.6M at Dec 31, 2022.
R&D expenses increased to $18.3M from $10.9M, driven by advancing zetomipzomib and KZR-261 programs.
PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis on track to initiate in H1 2023.
KZR-261 dose escalation study enrolling Cohort 6; dose expansion expected H2 2023 with topline data mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kezar Life Sciences, Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021203

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.